Roche Korea announced on the 8th that Vabysmo has been approved by the Ministry of Food and Drug Safety (MFDS) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion.

With the approval, Vabysmo is now approved for 3 indications in Korea, including as a treatment for ▲neovascular (wet) age-related macular degeneration; ▲visual impairment due to diabetic macular edema; and ▲visual impairment due to macular edema secondary to retinal vein occlusion.

Retinal vein occlusion is the second leading cause of blindness due to retinal vascular disease. It primarily affects people over the age of 60 and can cause sudden vision loss.